Saudi Arabia advances chronic urticaria care through SSDDS-Novartis partnership

SAUDI ARABIA—Saudi Arabia’s Saudi Society of Dermatology and Dermatologic Surgery (SSDDS) and Novartis Saudi Arabia have launched a strategic partnership to boost medical education and enhance care for patients with chronic urticaria (CU).

This common skin condition causes itchy hives that last more than six weeks, affecting daily life for many.

Through a new Letter of Intent, the two organizations commit to building stronger care pathways across the Kingdom.

They focus on delivering evidence-based training, raising awareness about the disease, and guiding patients toward better outcomes.

This effort directly supports SSDDS’s goal of improving dermatology practices and professional skills nationwide.

At the same time, it builds on Novartis’s deep dedication to patient-focused innovations in immuno-dermatology.

Together, they address key gaps in CU management, where many patients face delays in diagnosis and treatment.

Dr. Abdullah Suleiman Al-Akeel, President of SSDDS, highlighted the need for ongoing education and scientific collaboration.

He explained that advancing skin care in Saudi Arabia demands a sharp focus on patient needs.

This partnership with Novartis creates a vital platform to increase awareness of chronic urticaria among dermatologists and other healthcare professionals.

As a result, it helps elevate care standards throughout the country, making treatments more effective and accessible.

Amir Abdelaziz, Country President at Novartis Saudi Arabia, emphasized their leadership in immuno-dermatology.

Novartis goes beyond just supplying medications; they actively work to transform how patients experience care.

In line with their mission to rethink medicine, this collaboration empowers people with chronic urticaria through reliable information and support.

From the first outbreak of symptoms to expert diagnosis, patients now gain smoother, more informed paths to relief.

Dr. Dana Alessa, Head of SSDDS’s Scientific Committee, stressed the emotional toll of chronic urticaria.

This condition often brings severe distress, yet doctors frequently overlook or misdiagnose it. Education changes that picture.

By generating local research and partnering with top medical groups, SSDDS and Novartis promote quicker diagnoses and smarter treatment choices.

Ultimately, these steps lead to improved quality of life for patients everywhere in the Kingdom.

The partnership bridges industry expertise with medical insights, sharpening disease knowledge and speeding up management strategies.

Healthcare providers gain tools for early intervention, while patients benefit from clearer guidance.

This united approach strengthens Saudi Arabia’s healthcare system, fostering resilience against challenging conditions like chronic urticaria.